依达拉奉治疗急性脑出血的疗效评价  

Chinical efficacy of edaravone on acute cerebral hemorrhage

作　　者：王国栋[1] 沈翔[1] 许志祥[1] 

机构地区：[1]上海交通大学附属第一人民医院神经科,上海200080

出　　处：《海南医学》2007年第11期3-4,共2页Hainan Medical Journal

摘　　要：目的评价羟自由基清除剂——依达拉奉注射液治疗脑出血(CH)的有效性。方法将71例起病48小时内的CH患者随机均分为治疗组(36例)和对照组(35例)。治疗组在脱水(甘露醇和/或白蛋白),抗感染等常规治疗的基础上,给予依达拉奉30mg加生理盐水100ml静脉滴注,30min内滴完,每日2次,共14d。治疗组于治疗前及治疗后第30天分别进行欧洲卒中评分(ESS),以治疗第30dESS增分率作为主要疗效判断标准。结果治疗30d后,结果30d后治疗组、对照组ESS增分率分别为(54.1±25.9)%、(28.8±22.9)%,两组相比差异有极显著性(P<0.001)。结论依达拉奉治疗ICH是有效的。Objective To evaluate the efficacy of edaravone, a novel hydroxy-free radical scavenger, on the treatment of acute cerebral hemorrhage （CH）. Methods 71 CH cases enrolled within 48h of onset were divided into treatment group（n=36） and control group（n=35） randomly. Edaravone was infused at a dose of 30mg, twice a day, for 14 days. Meanwhile, the dehydrater （mannitol and or albumin） were taken as basic treatment. The therapies of the placebo group were similar to those of Edaravone group except for Edaravone. Before treatment and at 30th day after treatment, the neurological deficits and activities of daily living were evaluated using European Stroke Scale （ESS）. All the patients were followed up for survival at 30th dav the increase rate of ESS was evaluated. There were significan difference between Edaravone group （48.2±16.4）% and the placebo group （29.7±11.1）% （P〈0.001）. Conclusions Edaravone is a new effective neuroprotective agent for treating CH.

关 键 词：依达拉奉 脑出血 羟自由基清除剂 

分 类 号：R743.34[医药卫生—神经病学与精神病学]